(Q39127318)

9 September 2017

title

High dose genistein aglycone therapy is safe in patients with mucopolysaccharidoses involving the central nervous system (English)

1 reference

9 September 2017

Katherine H Kim

1

1 reference

9 September 2017

Charlotte Dodsworth

series ordinal

2

1 reference

9 September 2017

Andrea Paras

series ordinal

3

1 reference

9 September 2017

Barbara K Burton

series ordinal

4

1 reference

9 September 2017

publication date

21 June 2013

1 reference

Molecular Genetics and Metabolism

9 September 2017

published in

1 reference

9 September 2017

volume

109

1 reference

9 September 2017

issue

4

1 reference

9 September 2017

page(s)

382-385

1 reference

Sanfilippo syndrome: a mini-review

9 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.06.012

Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.06.012

The first 5 years of clinical experience with laronidase enzyme replacement therapy for mucopolysaccharidosis I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.06.012

Genistein-mediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidoses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.06.012

Genistein-mediated inhibition of glycosaminoglycan synthesis, which corrects storage in cells of patients suffering from mucopolysaccharidoses, acts by influencing an epidermal growth factor-dependent pathway.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.06.012

Storage correction in cells of patients suffering from mucopolysaccharidoses types IIIA and VII after treatment with genistein and other isoflavones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.06.012

Genistein reduces lysosomal storage in peripheral tissues of mucopolysaccharide IIIB mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.06.012

Genistein reduces glycosaminoglycan levels in a mouse model of mucopolysaccharidosis type II

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.06.012

Genistein improves neuropathology and corrects behaviour in a mouse model of neurodegenerative metabolic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.06.012

Genistin-rich soy isoflavone extract in substrate reduction therapy for Sanfilippo syndrome: An open-label, pilot study in 10 pediatric patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.06.012

Improvement in the range of joint motion in seven patients with mucopolysaccharidosis type II during experimental gene expression-targeted isoflavone therapy (GET IT)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.06.012

Genistein supplementation in patients affected by Sanfilippo disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.06.012

Genistein in Sanfilippo disease: a randomized controlled crossover trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.06.012

Scoring evaluation of the natural course of mucopolysaccharidosis type IIIA (Sanfilippo syndrome type A)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.06.012

10.1016/J.YMGME.2013.06.012

7 January 2021

Identifiers

DOI

1 reference

9 September 2017

1 reference